financetom
Business
financetom
/
Business
/
Lululemon slashes annual outlook on demand, tariff woes and shares plummet 14%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lululemon slashes annual outlook on demand, tariff woes and shares plummet 14%
Sep 4, 2025 1:55 PM

(Reuters) -Lululemon Athletica ( LULU ) slashed its annual revenue and profit forecasts on Thursday, signaling a slowdown in demand going into the crucial holiday season as consumers cut down spending, alongside tariff pressures. 

Shares of the company fell about 14% after the closing bell.

The sportswear maker's new products have failed to spark a wave of buying from consumers grappling with inflation and the Trump administration's volatile trade policy.

Lululemon's dour forecast for the second half of the year comes at a time when U.S. holiday spending is expected to see its steepest drop since the pandemic as Gen Z shoppers in particular pull back on spending, according to a PwC survey. 

The outlook includes a tariff hit of about $240 million on gross margin, including mitigation efforts, pricing actions, current higher levels of tariffs on imports into the U.S. and the removal of the de minimis exemption, the company said.

De minimis is a U.S. customs exemption that allows duty-free entry and minimal paperwork for international shipments under $800. The exemption removal became effective on August 29.

The company, which introduces new product variations every Thursday said in June it was planning to take strategic and modest price hikes alongside attempts to cut costs and negotiate with vendors, in a bid to reduce tariff impacts.

Lululemon manufactured 40% of its products in Vietnam, and sourced 28% of its fabrics from mainland China, as of 2024, posing risks as goods imported from these countries to the U.S. face heavy duties.

The yogawear firm now expects annual revenue between $10.85 billion and $11 billion, compared with its prior forecast of $11.15 billion to $11.30 billion.

It also forecast annual profit between $12.77 and $12.97 per share, compared with previous expectations of $14.58 to $14.78 apiece. 

Revenue for the second quarter, ended August 3, rose 7% to $2.53 billion, largely in line with analysts' expectations, while earnings per share of $3.10 beat estimates of $2.88, according to data compiled by LSEG.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Iqvia, Salesforce Collaborate to Accelerate Life Sciences Cloud Development
Iqvia, Salesforce Collaborate to Accelerate Life Sciences Cloud Development
Apr 8, 2024
04:41 PM EDT, 04/08/2024 (MT Newswires) -- Iqvia Holdings ( IQV ) and Salesforce ( CRM ) said Monday they will combine their capabilities in data, artificial intelligence and technology to develop an advanced customer engagement platform for the global life sciences industry. Under their expanded partnership, innovations from Iqvia's ( IQV ) orchestrated customer engagement platform will be applied...
--Ellington Financial Keeps Monthly Dividend at $0.13 a Share, Payable May 28 to Holders of Record April 30
--Ellington Financial Keeps Monthly Dividend at $0.13 a Share, Payable May 28 to Holders of Record April 30
Apr 8, 2024
04:41 PM EDT, 04/08/2024 (MT Newswires) -- Price: 11.5, Change: +0.04, Percent Change: +0.35 ...
Jfrog Insider Sold Shares Worth $255,600, According to a Recent SEC Filing
Jfrog Insider Sold Shares Worth $255,600, According to a Recent SEC Filing
Apr 8, 2024
04:33 PM EDT, 04/08/2024 (MT Newswires) -- Tali Notman, Chief Revenue Officer, on April 05, 2024, sold 6,000 shares in Jfrog ( FROG ) for $255,600. Following the Form 4 filing with the SEC, Notman has control over a total of 522,348 shares of the company, with 522,348 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1800667/000141588924010491/xslF345X03/form4-04082024_080432.xml ...
Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing
Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing
Apr 8, 2024
04:42 PM EDT, 04/08/2024 (MT Newswires) -- Daniel Bradbury, Director, on April 04, 2024, sold 20,923 shares in Castle Biosciences ( CSTL ) for $441,853. Following the Form 4 filing with the SEC, Bradbury has control over a total of 23,423 shares of the company, with 4,655 shares held directly and 18,768 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1447362/000144736224000037/xslF345X03/wk-form4_1712608298.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved